Go to content
Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 19 okt 2015 - 08:06
Statutaire naam Vivoryon Therapeutics N.V.
Titel Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago
Bericht Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago Presentation at the Society for Neuroscience (SfN) Annual Meeting HALLE/SAALE, Germany, 19 October 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), presented data on its specific pGlu3-Abeta monoclonal antibody at Neuroscience 2015, the 45th annual meeting of the Society for Neuroscience (SfN) in Chicago, USA. The data presented result from a collaboration between Probiodrug and the research team led by Associate Professor Cynthia Lemere from the Center for Neurologic Diseases at the Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Datum laatste update: 19 februari 2025